Key result
PCSK9 inhibitors reduce Lp(a) by ~27% compared with placebo.
Why the study?
Do PCSK9 inhibitors reduce Lp(a) levels compared to placebo?
Meta-Analysis
Do PCSK9 inhibitors reduce Lp(a) levels compared to placebo?
Effect estimate: 27% reduction
PCSK9 inhibitors reduce Lipoprotein(a) levels by an average of 27%, with the effect associated with changes in LDL-C and apolipoprotein B.
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels. The primary outcome was percent change in Lp(a) levels. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences. Results: interaction < 0.01. Conclusions: PCSK9is reduce Lp(a) levels by an average of 27%. Mean percent change in low-density lipoprotein cholesterol and apolipoprotein B were associated with treatment effect.
No takes yet. Share an insight, caveat, or question.
Rivera et al. (2025) reported a meta-analysis. PCSK9 inhibitors vs. placebo was evaluated on percent change in Lp(a) levels (27% reduction). PCSK9 inhibitors reduced Lipoprotein(a) levels by an average of 27% compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: